Pitavastatin Magnesium

WINNIPEG, MB / ACCESS Newswire / September 8, 2026 / Medicure Inc. (" Medicure " or the " Company ") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced that the design, rationale and baseline data from its MEND-PNPO Phase 3 study ( ClinicalTrials.gov NCT04706013 ) are being presented at the 16th European Epilepsy Congress (EEC), taking place September 5-9, 2026, at the Megaron Athens International Conference Centre in Athens, Greece. MEND-PNPO is a pivotal trial evaluating MC-1 for the treatment of Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency. The poster, titled "Pharmaceutical Grade Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency: MEND-PNPO Study Design and Rationale," is presented by lead investigator Dr. Phillip Pearl (Director of Epilepsy and Clinical Neurophysiology at Boston Children's Hospital and William G. Lennox Chair and Professor of Neurology at Harvard Medical School, Boston, MA), together with co-investigators from study sites in the United States, Australia and Europe. The presentation outlines the study design, primary and secondary endpoints, MC-1 dosing regimens, and baseline pyridoxal 5'-phosphate (P5P) levels among enrolled patients. MEND-PNPO is a 52-week, Phase 3, open-label, multi-center, externally controlled study evaluating MC-1, a pharmaceutical-grade oral formulation of P5P, in patients aged 2 years and older with genetically confirmed PNPO deficiency. Enrollment began in January 2023 and is expected to be completed in 2026. As presented at EEC, nine patients have been enrolled to date and three have completed the one-year study. Baseline P5P treatment regimens ranged from 14 to 58 mg/kg/day and baseline steady-state P5P levels ranged from 59.8 to 165 ng/mL. Medicure aims to enroll approixamtely 10 patients with confirmed PNPO deficiency in the trial. Please note, MC-1 is not FDA-approved. The safety and effectiveness of MC-1 has not been established. PNPO deficiency is an ultra-rare inherited neurometabolic disorder caused by mutations in the PNPO gene, resulting in an inability to produce adequate levels of pyridoxal 5'-phosphate (P5P), the active form of vitamin B6. The condition commonly presents in newborns and infants with severe, difficult-to-control seizures and can lead to significant developmental impairment, neurological dysfunction, and death if untreated. Lifelong P5P therapy is typically required, yet no pharmaceutical-grade P5P product is approved. Medicure will also present the MEND-PNPO study at two North American meetings later this year: the Child Neurology Society (CNS) Annual Meeting, taking place October 14-17, 2026 at the Palais des congrès de Montréal in Montréal, Québec, Canada, and the American Epilepsy Society (AES) Annual Meeting, taking place December 4-8, 2026 at the Colorado Convention Center in Denver, Colorado, USA. "Presenting MEND-PNPO to the European epilepsy community is an important step in building awareness of PNPO deficiency and of the need for a standardized, pharmaceutical-grade P5P therapy," said Albert D. Friesen, President, Chief Executive Officer of Medicure and Chair of its Board of Directors. "We are grateful to the patients, families and investigators taking part in this study as we work to bring the first approved therapy for PNPO deficiency to patients in need." About Medicure Inc. Medicure is a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The present focus of the Company is the marketing and distribution of AGGRASTAT ® (tirofiban hydrochloride) injection and ZYPITAMAG ® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug Inc. ("Marley Drug"), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug ® is committed to improving access to medications for all Americans together with exceptional customer service and free home delivery. Medicure also operates Gateway Medical Pharmacy ("Gateway"), located in Portland, Oregon in a medical office building near major transportation lines and multiple healthcare clinics and centers. In addition to regular customers, the pharmacy services multiple long-term care facilities and provides non-sterile compounding services. Medicure also operates West Olympia Pharmacy ("West Olympia"), located in Olympia, Washington in a medical office complex near multiple clinics. For more information visit . For more information about Medicure please visit . For additional information about AGGRASTAT ® , please visit or refer to the full Prescribing Information . For additional information about ZYPITAMAG ® , please visit or refer to the full Prescribing Information. To be added to Medicure's e-mail list, please visit: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors and estimates include, among others, the Company's future product revenues, expected results, including future revenue from P5P, the likelihood of receiving a priority review voucher from the United State Food and Drug Administration and the value of the voucher if sold, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its current Form 20F. AGGRASTAT ® (tirofiban hydrochloride) injection, ZYPITAMAG ® (pitavastatin) tablets, and Marley Drug ® are registered trademarks. For more information, please contact: Dr. Albert D. Friesen Chief Executive Officer Tel. 888-435-2220 Fax 204-488-9823 E-mail: info@medicure.com SOURCE: Medicure, Inc. View the original press release on ACCESS Newswire

2026年阿根廷极地游轮暴发汉坦病毒疫情，造成13人感染和3人离世，然而当下全球无获批特效药；加之新旧大陆毒株差异大、候选药缺广谱性、临床试验推进困难，基于这一严峻公共卫生困境，我们系统梳理三大药物研发路线与前沿技术，希望为抗汉坦病毒新药研发提供参考思路。导  读 2026年4月从阿根廷出发的极地游轮爆发汉坦病毒聚集疫情，世卫组织通报，累计出现13人确诊、3人死亡，这再次敲响人畜共患病防控警钟。汉坦病毒分为新旧大陆两大分支，欧亚毒株致肾综合征出血热，美洲毒株诱发致死率高达40%的心肺综合征，目前全球尚无获批特效药与预防性疫苗，临床上仅能依靠对症支持治疗。本文结合最新药学研究，系统拆解靶向病毒、靶向宿主、免疫疗法三大研发路线，梳理利巴韦林、法匹拉韦等候选药物作用机制，剖析毒株差异、临床试验开展难等行业痛点，同时展望AI辅助分子设计、类器官筛选等前沿技术，为大众科普病毒防控与新药研发前沿进展。图1 图文摘要2026年极地游轮爆发的汉坦病毒聚集疫情，让这种长期潜伏在啮齿动物体内的烈性病毒重回大众视野。作为布尼亚病毒目包膜RNA病毒，汉坦病毒依靠鼠类完成自然循环，分为新旧大陆两大谱系，致病特征天差地别：亚洲、欧洲流行的旧大陆毒株（Hantaan、Seoul病毒等）会损伤肾脏，引发肾综合征出血热；美洲独有的新大陆Sin Nombre、Andes病毒则会攻击心肺，诱发重症心肺综合征，危重病例死亡率最高可达40%，救治压力极大。更严峻的是，现阶段全球没有一款获批抗汉坦病毒特效药，也无通用人用预防疫苗，感染者只能依靠补液、脏器保护等支持疗法，巨大的临床缺口推动全球科研团队全力攻坚抗病毒新药。从病毒结构来看，汉坦病毒的三段负链RNA分别编码核衣壳蛋白（NP）、糖蛋白前体（GPC）、RNA依赖RNA聚合酶（RdRp），这三类高度保守蛋白是药物研发核心靶点，完整病毒生命周期（吸附入侵、脱壳、转录复制、组装释放）的每一步都可成为药物阻断位点，当前研发路径主要分为三大类。第一类是靶向病毒直接抗病毒药物，也是进展最成熟的方向。病毒入侵阶段，钙离子通道阻滞剂可阻断病毒黏附内皮细胞，cilnidipine、amlodipine等均在细胞实验中展现抗病毒活性；复制核心酶RdRp是最热门靶点，核苷类药物ribavirin、favipiravir可嵌入病毒RNA终止复制，二者联用还能提升药效；baloxavir靶向核酸内切酶结构域，阻断病毒“抢帽”转录过程；而全病毒最保守的NP蛋白，可被morin结合，破坏病毒核糖核蛋白组装，成为全新研发赛道。第二类靶向宿主抗病毒药物，跳出直接杀病毒思路，通过调控人体细胞通路缓解重症损伤。汉坦病毒会破坏血管内皮屏障，引发血管渗漏、脏器水肿，SFK激酶抑制剂dasatinib、pazopanib，酪氨酸激酶抑制剂Vandetanib，能够稳定血管钙粘蛋白，大幅减轻内皮通透性损伤；病毒会干扰人体胆固醇代谢，他汀类降脂药pitavastatin、atorvastatin可抑制胆固醇合成通路，显著降低细胞内病毒载量，从宿主层面切断病毒增殖条件。第三类免疫辅助疗法，作为重症救治补充手段。康复者血浆已在仓鼠动物模型中验证保护效果；中和单克隆抗体JL16、MIB22可强效中和安第斯病毒，体外中和活性优异，但仍存在抗原表位研究不足、抗体量产困难等局限，距离临床应用仍有距离。尽管候选药物不断涌现，研发转化仍存在多重现实难题。（1）新旧大陆毒株基因差异巨大，药物敏感性截然不同，例如ribavirin对欧洲普马拉病毒疗效微弱，多数候选药仅针对单一毒株，缺少广谱抗病毒能力；（2）汉坦病毒具有散发、低发的流行特点，难以开展大规模多中心临床试验，缺少高级别临床数据支撑药效；（3）缺少标准化动物模型，不同实验室预实验数据无法统一对照，拉长研发周期。总结与展望未来抗汉坦病毒药物研发将朝着广谱、多靶点、联合用药三大方向突破。一方面依托AI多模态学习、高通量虚拟筛选技术，同步靶向RdRp、NP、糖蛋白等保守位点，设计可覆盖全部毒株的广谱小分子药物；另一方面融合宿主调控与直接抗病毒机制，开发双靶点复合制剂，同步抑制病毒复制、保护血管内皮。同时在疫区开展针对性临床试验，积累真实世界疗效数据。随着病毒致病机制研究持续深入，三类研发策略持续完善，有望早日产出安全有效的防治药物，降低汉坦病毒所造成的全球公共卫生负担。责任编辑郑建伟   The Innovation